ReviewNature medicine2022
Delivering precision oncology to patients with cancer.
Review in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
206 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Factors that influence the uptake of precision-guided treatment recommendations in paediatric cancer: a systematic review.British journal of cancer · 2026Pooled it
- Insights into pet-based radiogenomics in oncology: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Pooled it
- Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Trial
- Epigenetic silencingCancer biology & therapy · 2026Article
- Why early pathology input matters in biologically rich cancer trials.British journal of cancer · 2026Review
- Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.Leukemia · 2026Review
- Article
- Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross-Sectional Study.Clinical pharmacology and therapeutics · 2026Article
- Article
- Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review.Translational lung cancer research · 2026Review
- Patient experiences of tissue donation and digital consent support in primary craniospinal tumour research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- RLASON-CDR: a reinforcement learning-driven adaptive synergistic optimization network for cancer drug response prediction.Briefings in bioinformatics · 2026Article
- In silico models in oncology, neurology, and epidemiology: systems-level and multiscale perspectives.NPJ systems biology and applications · 2026Review
- Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing.British journal of cancer · 2026Article
- Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.Cell death discovery · 2026Article
- Experiences accessing and receiving tumour genetic profiling in Victoria: a consumer-led cross-sectional survey study.BMC cancer · 2026Article
- Seesaw signatures capture trajectory-like transcriptomic shifts and enable compact tumour cell classification across cancers.Communications biology · 2026Article
- Molecular Traces of Gastric Cancer in Saliva: From Tissue Signatures to Salivary SLC5A5 as a Potential Biomarker.United European gastroenterology journal · 2026Observational
146 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.
Indexed as
Identifiers
35440717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.